保留乳头乳晕复合体乳房切除术在乳腺癌中的肿瘤学安全性
该单中心回顾性研究评估了2007至2016年2182例治疗性NSM的肿瘤学结局,其中对2007至2012年311例0-3期乳腺癌患者进行长期随访,中位随访51个月,局部区域复发率3.7%、远处复发率2.7%,5年无病生存率92.3%,全组无保留乳头乳晕复合体复发。
要点
- NSM术后局部区域复发率3.7%、远处复发率2.7%,肿瘤学结局可接受。
- 中位随访51个月,3年无病生存率95.7%,5年无病生存率92.3%。
- 2182例NSM全组无保留乳头乳晕复合体复发。
核心结论
- 乳腺癌患者行保留乳头乳晕复合体乳房切除术后局部区域和远处复发率处于可接受的低水平。
- 整个2182例NSM队列中无患者出现保留乳头乳晕复合体复发。
研究设计与样本
- 单中心回顾性队列研究,纳入2007至2016年连续施行的治疗性NSM共2182例。
- 长期结局评估对象为2007至2012年施行的311例0-3期乳腺癌NSM,其中浸润性癌240例(77%)、导管原位癌71例(23%)。
- NSM仅提供给无影像学或临床乳头受累证据的患者。
主要发现
- 中位随访51个月,17例患者出现癌症复发。
- 估计3年无病生存率95.7%,5年无病生存率92.3%。
- 局部区域复发11例(3.7%),远处复发8例(2.7%),2例同时出现局部区域和远处复发。
- 2例孤立远处复发患者发生乳腺癌相关死亡。
- 2182例NSM全队列中无保留乳头乳晕复合体复发。
临床怎么用
- 对于无乳头受累影像学或临床证据的乳腺癌患者,NSM可作为治疗选择之一。
- 术后需关注局部区域和远处复发,但保留乳头乳晕复合体本身复发风险在本系列中极低。
局限性
- 研究为单中心回顾性设计。
- 长期结局仅评估2007至2012年311例NSM,随访时间有限(中位51个月)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Nipple-sparing mastectomy (NSM) has gained popularity for breast cancer treatment and prevention. There are limited data about long-term oncologic safety of this procedure. STUDY DESIGN: We reviewed oncologic outcomes of consecutive therapeutic NSM at a single institution. Nipple-sparing mastectomy was offered to patients with no radiologic or clinical evidence of nipple involvement. RESULTS: There were 2,182 NSM performed from 2007 to 2016. Long-term outcomes were assessed in the 311 NSM performed in 2007 to 2012 for Stages 0 to 3 breast cancer; 240 (77%) NSM were for invasive cancer and 71 (23%) were for ductal carcinoma in situ. At 51 months median follow-up, 17 patients developed a recurrence of their cancer. Estimated disease-free survival was 95.7% at 3 years and 92.3% at 5 years. There were 11 (3.7%) locoregional recurrences and 8 (2.7%) distant recurrences; 2 patients had simultaneous locoregional and distant recurrences. There were 2 breast cancer-related deaths in patients with isolated distant recurrences. No patient in the entire 2,182 NSM cohort has had a recurrence in the retained nipple-areola complex. CONCLUSIONS: Rates of locoregional and distant recurrence are acceptably low after nipple-sparing mastectomy in patients with breast cancer. No patient in our series has had a recurrence involving the retained nipple areola complex.
引用
- Smith BL, Tang R, Rai U, et al. Oncologic Safety of Nipple-Sparing Mastectomy in Women with Breast Cancer. J Am Coll Surg. 2017. PMID: 28728962. doi:10.1016/j.jamcollsurg.2017.06.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。